AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$TRVI

Trevi Therapeutics, Inc.

Price · $TRVIvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $TRVI in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $TRVI in the last 30 days.

Top stories · $TRVIMore →
JAN 9·Investing.com IndiaHigh

Trevi Therapeutics schedules FDA meeting for chronic cough program By Investing.com

Trevi Therapeutics (NASDAQ: TRVI) has scheduled an End-of-Phase 2 meeting with the FDA in Q1 2026 to discuss its chronic cough program for idiopathic pulmonary fibrosis (IPF) patients, focusing on its investigational therapy Haduvio. The company plans to initiate a Phase 2b trial for refractory chronic cough in H1 2026 and expects to launch its Phase 3 program for nalbuphine ER in the IPF patient population in H1 2026. Despite being pre-revenue, Trevi boasts a strong financial position, with significant stock performance gains and positive analyst outlooks.

JAN 9·GuruFocus

Trevi Therapeutics (TRVI) Receives Reiterated 'Buy' Rating from HC Wainwright & Co. | TRVI Stock News

HC Wainwright & Co. has reiterated its 'Buy' rating for Trevi Therapeutics (TRVI), maintaining a price target of $21.00, signaling confidence in the company's future growth. This follows a series of positive analyst ratings from various firms in late 2025, which also raised price targets. Trevi Therapeutics, a clinical-stage biopharmaceutical company, is focused on developing Haduvio for chronic cough indications and prurigo nodularis.

JAN 8·Investing.com South Africa

Trevi Therapeutics schedules FDA meeting for chronic cough program By Investing.com

Trevi Therapeutics (NASDAQ:TRVI) is set to meet with the FDA in Q1 2026 to discuss its chronic cough program for idiopathic pulmonary fibrosis (IPF) and plans a Phase 2b trial for refractory chronic cough in H1 2026. The company, which is pre-revenue but has seen significant stock gains and strong financial positioning, is developing Haduvio (oral nalbuphine ER), which has shown a statistically significant reduction in cough frequency. Analysts have issued "Buy" ratings and price targets, indicating potential upside, as the company addresses a significant unmet medical need for chronic cough in IPF and non-IPF interstitial lung disease patients.

News on $TRVI

All news →